Holly Edwards Selected Research

Therapeutics

2/2024	Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.
12/2023	Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
11/2022	Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
7/2022	"FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.
1/2022	The paradox of Myeloid Leukemia associated with Down syndrome.
1/2021	The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
12/2020	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.
11/2019	Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
1/2019	A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics.
1/2015	Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Holly Edwards Research Topics

Disease

33	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2024 - 11/2010
11	Neoplasms (Cancer) 12/2023 - 01/2013
7	Leukemia 12/2023 - 09/2009
4	Down Syndrome (Down's Syndrome) 01/2022 - 01/2011
4	Pancreatic Neoplasms (Pancreatic Cancer) 07/2017 - 12/2014
3	Acute Megakaryoblastic Leukemia (Leukemia, Megakaryocytic) 01/2013 - 09/2009
2	Carcinogenesis 07/2022 - 01/2019
2	Neuroblastoma 01/2015 - 01/2013
2	Epilepsy (Aura) 12/2012 - 11/2010
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2022
1	Infections 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2020
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019
1	Disease Progression 01/2017
1	Diffuse Intrinsic Pontine Glioma 01/2017

Drug/Important Bio-Agent (IBA)

12	venetoclaxIBA 12/2023 - 01/2016
10	Cytarabine (Cytosar-U)FDA LinkGeneric 02/2024 - 11/2010
6	PanobinostatIBA 01/2017 - 01/2013
5	Histone Deacetylase InhibitorsIBA 01/2020 - 11/2010
5	Histone Deacetylases (Histone Deacetylase)IBA 01/2020 - 02/2011
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 01/2013
4	adavosertibIBA 01/2015 - 08/2014
3	CUDC-907IBA 01/2021 - 11/2019
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2011
2	AnthracyclinesIBA 02/2024 - 02/2015
2	ME-344IBA 12/2023 - 04/2023
2	IsoflavonesIBA 12/2023 - 04/2023
2	gilteritinibIBA 01/2022 - 11/2019
2	fms-Like Tyrosine Kinase 3IBA 01/2022 - 01/2021
2	obatoclaxIBA 02/2015 - 12/2014
2	Valproic Acid (Depakote)FDA LinkGeneric 12/2012 - 11/2010
1	Oxidoreductases (Dehydrogenase)IBA 01/2024
1	Azacitidine (5 Azacytidine)FDA Link 10/2023
1	AZD5991IBA 12/2022
1	MRX-2843IBA 01/2022
1	CohesinsIBA 01/2022
1	IACS-010759IBA 08/2020
1	voruciclibIBA 01/2020
1	Androgen Receptors (Androgen Receptor)IBA 01/2020
1	midostaurinIBA 11/2019
1	Intercalating AgentsIBA 01/2019
1	Annexin A5IBA 01/2019
1	Topoisomerase II InhibitorsIBA 01/2019
1	RNA Polymerase I (Polymerase I, RNA)IBA 01/2019
1	vosaroxinIBA 01/2019
1	Propidium (Propidium Iodide)IBA 01/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2018
1	Reactive Nitrogen SpeciesIBA 07/2018
1	SCH772984IBA 07/2017
1	VS-5584IBA 07/2017
1	Gemcitabine FDA Link 06/2017
1	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 06/2017
1	dipinacoline glutamateIBA 01/2017
1	piperlongumineIBA 01/2016
1	Chloroquine (Aralen)FDA LinkGeneric 12/2014
1	Phosphotransferases (Kinase)IBA 10/2014
1	LY2603618IBA 01/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2013
1	Etoposide (VP 16)FDA LinkGeneric 01/2013
1	Cisplatin (Platino)FDA LinkGeneric 01/2013
1	Transcription Factors (Transcription Factor)IBA 01/2013
1	Purine NucleosidesIBA 12/2012
1	Clofarabine (Clolar)FDA Link 12/2012
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2009

Therapy/Procedure

15	Drug Therapy (Chemotherapy) 12/2023 - 09/2009
14	Therapeutics 02/2024 - 01/2011
1	Castration 01/2020
1	Induction Chemotherapy 01/2019
1	Re-Irradiation 01/2017